Twist Bioscience to Report Fiscal 2026 Fourth Quarter Financial Results
Twist Bioscience Corporation has announced its schedule to release its financial results for the fourth quarter of fiscal year 2026.
Stocks · News reference
Barclays Maintains Overweight on Twist Bioscience, Raises Price Target to $215
Barclays analyst Luke Sergott maintains Twist Bioscience (NASDAQ:TWST) with a Overweight and raises the price target from $112 to $215.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Biotech Giants vs. Emerging Innovators: Which ETF Is the Better Buy?
The article compares two biotech ETFs: VanEck Biotech ETF (BBH), which concentrates on 26 industry leaders like Amgen and Gilead Sciences, versus State Street SPDR S&P Biotech ETF (XBI), which provides broad exposure to 165 companies including emerging innovators. While both have identical 0.35% expense ratios and 0.4% dividend yields, XBI offers lower volatility risk and is recommended as the better buy for long-term investors seeking exposure to the industry's next big winners.
TD Cowen Maintains Buy on Twist Bioscience, Raises Price Target to $190
Canaccord Genuity Maintains Buy on Twist Bioscience, Raises Price Target to $205
Canaccord Genuity analyst Kyle Mikson maintains Twist Bioscience (NASDAQ:TWST) with a Buy and raises the price target from $120 to $205.